• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Liquidia announces initiation of Phase 3 trial of trepostinil DPI for PAH

A Phase 3 trial of Liquidia Technologies’ LIQ861 treprostinil DPI for the treatment of pulmonary arterial hypertension (PAH) is underway, the company said. The study is expected to enroll a minimum of 100 PAH patients in the US, with topline data anticipated in 2019.

LIQ861, a dry powder formulation based on Liquidia’s PRINT particle engineering technology, is one of two products in the company’s pipeline. At least one other dry powder formulation for inhalation developed by Liquidia and licensed to GSK is in development.

Liquidia Technologies CEO Neal Fowler said, “We are committed to improving the daily experience of those living with PAH by advancing the clinical development of LIQ861. LIQ861 shows the potential of our PRINT® technology to optimize safety, efficacy and convenience of therapeutics. The initiation of our trial marks an important milestone for Liquidia, for those living with PAH and for the PAH community at large. We believe that we are well positioned to advance LIQ861 through Phase 3 clinical development.”

Read the Liquidia Technologies press release.

Share

published on January 3, 2018

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews